Mitomycin

Search with Google Search with Bing

Information
Drug Name
Mitomycin
Description
Entry(CIViC)
7
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
pancreatic cancer PALB2 BIALLELIC INACTIVATION PALB2 BIALLELIC INACTIVATION C Predictive Supports Sensitivity/Response Somatic 4 21135251 Detail
pancreatic cancer FANCC LOSS-OF-FUNCTION FANCC LOSS-OF-FUNCTION D Predictive Supports Sensitivity/Response Unknown 3 16243825 Detail
pancreatic cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION D Predictive Supports Sensitivity/Response Rare Germline 2 16243825 Detail
pancreatic adenocarcinoma RB1 OVEREXPRESSION
( ENST00000267163.6 ) RB1 OVEREXPRESSION
( ENST00000267163.6 ) 		D Predictive Supports Resistance Somatic 2 11792751 Detail
stomach carcinoma TP53 p.Arg273Cys (p.R273C)
( ENST00000576024.2, ENST00000510385.5, ENST00000504937.5, ENST00000604348.6, ENST00000269305.9, ENST00000359597.8, ENST00000420246.6, ENST00000445888.6, ENST00000413465.6, ENST00000455263.6, ENST00000504290.5, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) TP53 p.Arg273Cys (p.R273C)
( ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) 		C Predictive Does Not Support Sensitivity/Response Somatic 3 14514923 Detail
stomach carcinoma TP53 p.Tyr220Cys (p.Y220C)
( ENST00000510385.5, ENST00000504937.5, ENST00000604348.6, ENST00000576024.2, ENST00000504290.5, ENST00000269305.9, ENST00000359597.8, ENST00000618944.4, ENST00000619186.4, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) TP53 p.Tyr220Cys (p.Y220C)
( ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) 		C Predictive Supports Sensitivity/Response Somatic 3 14514923 Detail
stomach cancer TP53 OVEREXPRESSION
( ENST00000269305.9 ) TP53 OVEREXPRESSION
( ENST00000269305.9 ) 		B Predictive Supports Sensitivity/Response Somatic 4 14514923 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
In a patient with gemcitabine-refractory pancreati... PALB2 PALB2 BIALLELIC INACTIVATION PALB2 BIALLELIC INACTIVATION Sensitivity true CIViC Evidence detail
In the pancreatic cell lines PL11 (FANCC homozygou... FANCC FANCC LOSS-OF-FUNCTION FANCC LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In pancreatic cell lines PL11 (FANCC-deficient) an... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In Capan-1 cell lines engineered to reduce pRB exp... RB1 RB1 OVEREXPRESSION
( ENST00000267163.6 ) RB1 OVEREXPRESSION
( ENST00000267163.6 ) 		Resitance or Non-Reponse true CIViC Evidence detail
A female patient taking part in a 25 patient gastr... TP53 TP53 p.Arg273Cys (p.R273C)
( ENST00000576024.2, ENST00000510385.5, ENST00000504937.5, ENST00000604348.6, ENST00000269305.9, ENST00000359597.8, ENST00000420246.6, ENST00000445888.6, ENST00000413465.6, ENST00000455263.6, ENST00000504290.5, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) TP53 p.Arg273Cys (p.R273C)
( ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) 		Sensitivity false CIViC Evidence detail
A male patient taking part in a 25 patient gastric... TP53 TP53 p.Tyr220Cys (p.Y220C)
( ENST00000510385.5, ENST00000504937.5, ENST00000604348.6, ENST00000576024.2, ENST00000504290.5, ENST00000269305.9, ENST00000359597.8, ENST00000618944.4, ENST00000619186.4, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) TP53 p.Tyr220Cys (p.Y220C)
( ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) 		Sensitivity true CIViC Evidence detail
In a Phase II trial of 25 patients with metastaic ... TP53 TP53 OVEREXPRESSION
( ENST00000269305.9 ) TP53 OVEREXPRESSION
( ENST00000269305.9 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT06462001 Active, not recruiting Phase 3 BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer December 10, 2020 December 1, 2026
NCT03775265 Active, not recruiting Phase 3 Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer June 3, 2019 June 1, 2027
NCT04216290 Active, not recruiting Phase 2 A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study) March 17, 2021 June 30, 2026
NCT00981656 Completed Phase 2 Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer November 2009 August 15, 2023
NCT01004978 Completed Phase 3 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery October 28, 2009 December 21, 2022
NCT01017640 Completed Phase 1 Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors October 2009
NCT02891447 Completed Phase 2 Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer September 1, 2016 April 11, 2023
NCT03617913 Completed Phase 2 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer September 19, 2018 July 27, 2020
NCT03766425 Completed Early Phase 1 Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy. June 14, 2017 July 31, 2019
NCT00003907 Completed Phase 2 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver December 15, 1999 August 2012
NCT00148395 Completed Phase 3 Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. June 2002 April 2008
NCT00654888 Completed N/A Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy March 2005 February 2008
NCT04845490 Not yet recruiting Phase 2 Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy September 1, 2022 September 1, 2026
NCT06227065 Not yet recruiting Phase 2 Precise Neoadjuvant Chemoresection of Low Grade NMIBC October 2024 October 2029
NCT04107077 Recruiting Phase 2 Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer March 14, 2024 June 1, 2025
NCT04166318 Recruiting Phase 2 Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study January 2, 2020 December 31, 2029
NCT05672108 Recruiting Phase 2 Transarterial Chemoembolization for the Treatment of Lung Cancer May 12, 2023 October 31, 2024
NCT04329494 Recruiting Phase 1 PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer August 21, 2020 December 30, 2025
NCT04929028 Recruiting Phase 2 Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer August 9, 2022 September 15, 2029
NCT03914820 Recruiting N/A Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study. June 19, 2020 June 1, 2025
NCT05024734 Recruiting Phase 2 Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids November 17, 2022 November 16, 2026
NCT01171482 Terminated Phase 2 Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma November 2015 April 2016
NCT01671488 Terminated Phase 1/Phase 2 A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer February 2013 February 2018
NCT01843452 Terminated Phase 2 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal December 2012 May 2016
NCT03790384 Unknown status Phase 4 Sequential Combination Therapy in Bladder Cancer January 15, 2019 January 15, 2021
NCT04493073 Unknown status Early Phase 1 Conjunctival Vascularity Changes Usnig OCTA After Trabeculectomy December 1, 2020 March 1, 2022
NCT01953406 Withdrawn Phase 2 The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma November 2015 November 2015